Has David Axelrod, MD received payments from drug or device companies?

Yes. Drug and device makers reported $64,696 in general payments to David Axelrod, MD across 35 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Axelrod, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Axelrod, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Axelrod, MD

Transplant Surgery · Iowa City, IANPI 1477574820

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $55,648 of the $64,696 with a category attached, or 86.0%. 10 manufacturers reported payments, led by AstraZeneca at 40.4% of the total. Reporting peaked in 2024 at $31,570 and has fallen 57.3% since, to $13,484 in 2025.

$64,696in general payments, 2019–2025

Across 35 payments — averaging $1848.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$26K
Bridge To Life Ltd$18K
Sanofi$11K
Veloxis Pharmaceuticals, Inc.$8K
ZOLL Medical Corporation$393
Current Health, Inc.$175
plus $255 from 4 others

What the payments were for

Consulting fees$55,64886%
Travel & lodging$7,93812%
Food & beverage$1,1092%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	11	$26,151
Bridge To Life Ltd	7	$18,300
Sanofi	7	$11,171
Veloxis Pharmaceuticals, Inc.	1	$8,250
ZOLL Medical Corporation	1	$393
Current Health, Inc.	2	$175
Sanofi-aventis U.S. LLC	2	$161
Johnson & Johnson	2	$47
Conmed Corporation	1	$25
Merck	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$50,235

Medicare patients

Services billed

157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Valganciclovir Hcl	18	$6,681
Prednisone	11	$23

Paid to pharmacies, not to this prescriber.

Other transplant surgery in Iowa City

Hassan AzizIowa City$10K
Ramy El-DiwanyIowa City$4K
Alan HemmingIowa City$63
Alan ReedIowa City$63
Daniel KatzIowa City$25
Shengliang HeIowa City$21
Qasim ChaudhryDes Moines$12K
Juan ArenasDes Moines$5K
Mohammad AlzghariDes Moines$3K
Muhammad AbbasCoralville$25

See the full list for Iowa →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →